8-K: ESSA Pharma Presents Promising Phase 1/2 Clinical Data for Masofaniten at ESMO Congress

ESSA Pharma announced updated clinical data showing that masofaniten in combination with enzalutamide continues to be well-tolerated and demonstrates durable reductions in PSA levels in patients with metastatic castration-resistant prostate cancer.

Summary

• ESSA Pharma presented updated data from its Phase 1/2 study of masofaniten combined with enzalutamide at the 2024 ESMO Congress.
• The combination therapy continues to show good tolerability and significant reductions in prostate-specific antigen (PSA) levels in patients with metastatic castration-resistant prostate cancer (mCRPC).
• After a median follow-up of 15.2 months, the median time to PSA progression and radiographic progression-free survival have not yet been reached.
• In the Phase 1 dose escalation study, 88% of patients achieved a PSA50 reduction, 88% achieved a PSA90 reduction, 69% achieved a PSA90 reduction in less than 90 days, and 63% achieved a PSA level of less than 0.2 ng/mL.
• The recommended Phase 2 combination doses (RP2CDs) were identified as masofaniten 600 mg twice daily (BID) in combination with enzalutamide 160 mg once daily (QD).
• The Phase 2 dose expansion study is currently underway with 33 sites activated in the US, Canada, and Australia, and an additional 22 sites anticipated in Europe.

Sentiment

Score: 8

Explanation: The document presents very positive clinical data with strong efficacy signals and good tolerability, suggesting a promising future for the drug. The lack of reaching median progression times is also a very positive sign.

Positives

• The combination of masofaniten and enzalutamide is well-tolerated by patients.
• The therapy demonstrates rapid, deep, and durable reductions in PSA levels.
• A high percentage of patients achieved significant PSA reductions, including PSA90 and PSA <0.2 ng/mL.
• The median time to PSA progression and radiographic progression-free survival have not been reached, indicating a potentially long-lasting effect.
• The Phase 2 study is actively enrolling patients, expanding the reach of the research.

Negatives

• One patient experienced a Grade 3 rash, which was deemed probably related to the combination therapy, leading to an expansion of that cohort.
• Enzalutamide reduces masofaniten exposure, but twice daily dosing of masofaniten appears to mitigate this reduction.

Risks

• The study is still ongoing, and long-term efficacy and safety data are not yet available.
• The Phase 2 study is still enrolling, and results may vary as more data becomes available.
• There is a risk of adverse events, as evidenced by the Grade 3 rash experienced by one patient.
• The reduction in masofaniten exposure due to enzalutamide requires careful dosing management.

Future Outlook

ESSA Pharma anticipates providing further updates on the Phase 1/2 and Phase 2 studies in 2025.

Management Comments

• David Parkinson, MD, President and CEO of ESSA, stated that the data compares favorably to historical data for single agent enzalutamide treatment in the mCRPC patient population.
• The company is focused on enrolling patients in the Phase 2 dose expansion study.

Industry Context

This announcement is significant in the prostate cancer treatment landscape, as it presents a novel approach using a first-in-class N-terminal domain androgen receptor inhibitor in combination with an existing therapy. The results suggest a potential improvement over single-agent enzalutamide treatment, which is a common therapy for mCRPC.

Comparison to Industry Standards

• The results are being compared to historical data for single-agent enzalutamide treatment, suggesting that the combination therapy may offer superior outcomes.
• The high rates of PSA reduction, including PSA90 and PSA <0.2 ng/mL, are notable and could position masofaniten as a competitive option in the mCRPC treatment landscape.
• Other companies developing treatments for mCRPC include Astellas and Pfizer (enzalutamide), Johnson & Johnson (abiraterone), and Bayer (darolutamide).
• The lack of reaching median time to PSA progression and radiographic progression-free survival after 15.2 months is a positive sign compared to typical progression rates seen with standard therapies.

Stakeholder Impact

• Shareholders may view the positive clinical data favorably, potentially increasing the company's stock value.
• Patients with mCRPC may benefit from this new treatment option.
• Employees of ESSA Pharma may be motivated by the positive results and the potential for the drug to reach the market.

Next Steps

• Continue enrollment in the Phase 2 dose expansion study.
• Provide further updates on the Phase 1/2 and Phase 2 studies in 2025.

Key Dates

Keywords

masofaniten, enzalutamide, prostate cancer, mCRPC, PSA, clinical trial, androgen receptor, ESMO, Phase 1/2, Phase 2